These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 37001763)
1. Every-Other-Day Versus Once-a-Week Urethra-Sparing Prostate Stereotactic Body Radiation Therapy: 5-Year Results of a Randomized Phase 2 Trial. Zilli T; Jorcano S; Bral S; Symon Z; Rubio C; Bruynzeel AME; Ibrahimov R; Minn H; Oliveira A; Bertaut A; Constantin G; Miralbell R Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):791-798. PubMed ID: 37001763 [TBL] [Abstract][Full Text] [Related]
2. Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results. Zilli T; Jorcano S; Bral S; Rubio C; Bruynzeel AME; Oliveira A; Abacioglu U; Minn H; Symon Z; Miralbell R Cancer Med; 2020 May; 9(9):3097-3106. PubMed ID: 32160416 [TBL] [Abstract][Full Text] [Related]
3. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Alayed Y; Quon H; Ong A; Cheung P; Chu W; Chung H; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A Radiother Oncol; 2020 Aug; 149():8-13. PubMed ID: 32416376 [TBL] [Abstract][Full Text] [Related]
4. Urethra-Sparing Prostate Cancer Stereotactic Body Radiation Therapy: Sexual Function and Radiation Dose to the Penile Bulb, the Crura, and the Internal Pudendal Arteries From a Randomized Phase 2 Trial. Achard V; Zilli T; Lamanna G; Jorcano S; Bral S; Rubio C; Oliveira A; Bottero M; Bruynzeel AME; Ibrahimov R; Minn H; Symon Z; Constantin G; Miralbell R Int J Radiat Oncol Biol Phys; 2024 Jul; 119(4):1137-1146. PubMed ID: 38160915 [TBL] [Abstract][Full Text] [Related]
5. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial. Quon HC; Ong A; Cheung P; Chu W; Chung HT; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A Radiother Oncol; 2018 May; 127(2):206-212. PubMed ID: 29551231 [TBL] [Abstract][Full Text] [Related]
6. Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: Quality Assurance of a Randomized Phase 2 Trial. Jaccard M; Zilli T; Dubouloz A; Escude L; Jorcano S; Linthout N; Bral S; Verbakel W; Bruynzeel A; Björkqvist M; Minn H; Tsvang L; Symon Z; Lencart J; Oliveira A; Ozen Z; Abacioglu U; Pérez-Moreno JM; Rubio C; Rouzaud M; Miralbell R Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1047-1054. PubMed ID: 32535161 [TBL] [Abstract][Full Text] [Related]
7. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer. Potters L; Rana Z; Lee L; Cox BW Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):334-342. PubMed ID: 30721721 [TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
10. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial. Hannoun-Levi JM; Chand-Fouche ME; Pace-Loscos T; Gautier M; Gal J; Schiappa R; Pujol N Clin Transl Radiat Oncol; 2022 Nov; 37():64-70. PubMed ID: 36093342 [TBL] [Abstract][Full Text] [Related]
11. PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). Zamboglou C; Spohn SKB; Ruf J; Benndorf M; Gainey M; Kamps M; Jilg C; Gratzke C; Adebahr S; Schmidtmayer-Zamboglou B; Mix M; Bamberg F; Zschaeck S; Ghadjar P; Baltas D; Grosu AL Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1025-1035. PubMed ID: 35469897 [TBL] [Abstract][Full Text] [Related]
12. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial. Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659 [TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer. Wang MH; Vos LJ; Yee D; Patel S; Pervez N; Parliament M; Usmani N; Danielson B; Amanie J; Pearcey R; Ghosh S; Field C; Fallone BG; Murtha AD Pract Radiat Oncol; 2021; 11(5):384-393. PubMed ID: 33705985 [TBL] [Abstract][Full Text] [Related]
14. Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost. Richardson M; Sidhom M; Keall P; Leigh L; Ball H; Bucci J; Gallagher S; Greer P; Hayden AJ; Kneebone A; Pryor D; Siva S; Martin J Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1069-1078. PubMed ID: 36889514 [TBL] [Abstract][Full Text] [Related]
15. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933 [TBL] [Abstract][Full Text] [Related]
16. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes. Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102 [TBL] [Abstract][Full Text] [Related]
17. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer. Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146 [TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial. Sampath S; Frankel P; Vecchio BD; Ruel N; Yuh B; Liu A; Tsai T; Wong J Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):537-545. PubMed ID: 31733323 [TBL] [Abstract][Full Text] [Related]
19. Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer. Tambas M; Agaoglu F; Iribas A; Guveli M; Dizdar Y; Okutan M; Sahin D; Tenekeci N; Darendeliler E Value Health Reg Issues; 2016 Sep; 10():91-99. PubMed ID: 27881285 [TBL] [Abstract][Full Text] [Related]
20. 4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial. Fonteyne V; Sarrazyn C; Swimberghe M; De Meerleer G; Rammant E; Vanderstraeten B; Vanpachtenbeke F; Lumen N; Decaestecker K; Colman R; Villeirs G; Ost P Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):866-870. PubMed ID: 29485064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]